Entecavir and Tenofovir Treatment in Patients With Hepatitis B Virus-Related Cirrhosis: A Comparison of Results of Two-Year Treatment

Creative Commons License

Alkan E., AKIN M., Tuna Y.

KLIMIK JOURNAL, cilt.33, sa.3, ss.264-269, 2020 (ESCI) identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 33 Sayı: 3
  • Basım Tarihi: 2020
  • Doi Numarası: 10.5152/kd.2020.54
  • Dergi Adı: KLIMIK JOURNAL
  • Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), Scopus, Academic Search Premier, CAB Abstracts, CINAHL, EMBASE, Veterinary Science Database
  • Sayfa Sayıları: ss.264-269
  • Anahtar Kelimeler: Chronic hepatitis B, cirrhosis, entecavir, tenofovir, DISOPROXIL FUMARATE, MANAGEMENT, EFFICACY, SAFETY
  • Akdeniz Üniversitesi Adresli: Evet

Özet

Objective: Hepatitis B virus (HBV) infection is a common cause of cirrhosis and hepatocellular carcinoma. Interferons and nucleos(t)ide analogs are being used for the treatment of chronic HBV infection. Entecavir (ETV) and tenofovir disoproxil fumarate (TDF) are the strongest oral antiviral agents. In this study, we aimed to investigate efficacy and safety of ETV and TDF in treatment of naive cirrhotic patients infected with HBV.